1-20 of 134
Antoni Ribas
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3: Multiomics analyses reveal functional DNA, methylation pattern changes in clinical transgenic T-cell receptor cell therapy products

Giulia Protti, Cole Peters, Moe Kawakami, Conner Kidd, Varsha Subramanyam, Analynn Lechien, Andrew Dinh, Antoni Ribas, Matteo Pellegrini, Theodore S. Nowicki
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3.
https://doi.org/10.1158/1538-7445.AM2024-3
Published: 22 March 2024
View articletitled, Abstract 3: Multiomics analyses reveal functional DNA, methylation pattern changes in clinical transgenic T-cell receptor cell therapy products
Journal Articles

Abstract 6550: Biopsy analysis of trial S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with anti-PD-1 refractory melanoma

Katie M. Campbell, Zaid Bustami, Daniel G. Chen, Egmidio Medina, Cynthia R. Gonzalez, Nataly Naser Aldeen, Ignacio Baselga-Carretero, Agustin Vega-Crespo, Jessica Maxey, Jia M. Chen, Lawrence F. Kuklinski, Kari L. Kendra, Bartosz Chmielowski, Thach-Giao Truong, Nikhil I. Khushalani, Frances Collichio, Alexandra Ikeguchi, Adrienne I. Victor, Kim Margolin, Jeffrey A. Sosman, Sapna P. Patel, Siwen Hu-Lieskovan, James Moon, Shay Bellasea, Daniel K. Wells, Christine N. Spencer, Marshall A. Thompson, Michael Wu, Philip O. Scumpia, Ari VanderWalde, Antoni Ribas
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 6550.
https://doi.org/10.1158/1538-7445.AM2024-6550
Published: 22 March 2024
View articletitled, Abstract 6550: Biopsy analysis of trial S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with anti-PD-1 refractory melanoma
Journal Articles

Abstract CT009: S1512: High response rate with single agent anti-PD-1 in patients with metastatic desmoplastic melanoma

Kari Kendra, Shay Bellasea, Zeynep Eroglu, Siwen Hu-Lieskovan, Katie M. Campbell, William Carson, David Wada, Jose A. Plaza, Jeffrey Sosman, Gino K. IN, Alexandra Ikeguchi, John Hyngstrom, Andres Brohl, Nikhil I. Khushalani, Joseph Markowitz, George Negrea, Samer Kasbari, Gary C. Doolittle, Umang Swami, Toni Roberts, Sapna P. Patel, Elad Sharon, James Moon, Michael C. Wu, Antoni Ribas
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT009.
https://doi.org/10.1158/1538-7445.AM2023-CT009
Published: 14 April 2023
View articletitled, Abstract CT009: S1512: High response rate with single agent anti-PD-1 in patients with metastatic desmoplastic melanoma
Journal Articles

Abstract CT069: Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic BRAF V600-mutant melanoma

Dirk Schadendorf, Reinhard Dummer, Caroline Robert, Antoni Ribas, Ryan J. Sullivan, Timothy Panella, Meredith McKean, Edgardo S. Santos, Jill Clancy, Anna Polli, Alessandra di Pietro, Paolo A. Ascierto
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT069.
https://doi.org/10.1158/1538-7445.AM2023-CT069
Published: 14 April 2023
View articletitled, Abstract CT069: Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic BRAF V600-mutant melanoma
Journal Articles

Abstract LB251: Blocking genomic instability delays acquired resistance to MAPK inhibitor therapy in melanoma

Prashanthi Dharanipragada, Xiao Zhang, Sixue Liu, Shirley H. Lomeli, Aayoung Hong, Yan Wang, Zhentao Yang, Agustin Vega-Crespo, Antoni Ribas, Stergios J. Moschos, Gatien Moriceau, Roger S. Lo
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): LB251.
https://doi.org/10.1158/1538-7445.AM2023-LB251
Published: 14 April 2023
View articletitled, Abstract LB251: Blocking genomic instability delays acquired resistance to MAPK inhibitor therapy in melanoma
Journal Articles

Abstract CT023: Phase 1 trial of CD19/CD20 bispecific chimeric antigen receptor-engineered naïve/memory T cells for relapsed or refractory non-Hodgkin lymphoma

Benjamin R. Puliafito, Christopher Walthers, Brenda Ji, Sanaz N. Ghafouri, Jacob Naparstek, Jacqueline Trent, Jia M. Chen, Mobina Roshandell, Caitlin Harris, Mobina Khericha, Thomas Schweppe, Beata Berent-Maoz, Stanley B. Gosliner, Amr Almaktari, Melanie Ayala Ceja, Martin S. Allen-Auerbach, Jonathan Said, Karla Nawaly, Monica Mead, Sven de Vos, Patricia A. Young, Caspian Oliai, Gary J. Schiller, John M. Timmerman, Antoni Ribas, Yvonne Y. Chen, Sarah M. Larson
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT023.
https://doi.org/10.1158/1538-7445.AM2023-CT023
Published: 14 April 2023
View articletitled, Abstract CT023: Phase 1 trial of CD19/CD20 bispecific chimeric antigen receptor-engineered naïve/memory T cells for relapsed or refractory non-Hodgkin lymphoma
Journal Articles

Abstract 5965: B2M loss of heterozygosity in melanoma is associated with increased numbers of activated NK cells and higher expression of the NK cell inhibitory ligand, HLA-G

Mildred Galvez, Katie M. Campbell, Egmidio Medina, Antoni Ribas
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5965.
https://doi.org/10.1158/1538-7445.AM2023-5965
Published: 04 April 2023
View articletitled, Abstract 5965: B2M loss of heterozygosity in melanoma is associated with increased numbers of activated NK cells and higher expression of the NK cell inhibitory ligand, HLA-G
Journal Articles

Abstract 4532: Spatial profiling delineates tumor-T-cell dynamics in anti-PD-1-refractory melanoma treated with ipilimumab or ipilimumab plus nivolumab

Nataly Naser Al Deen, Katie M. Campbell, Egmidio Medina, Cynthia R. Gonzalez, Philip O. Scumpia, Antoni Ribas
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4532.
https://doi.org/10.1158/1538-7445.AM2023-4532
Published: 04 April 2023
View articletitled, Abstract 4532: Spatial profiling delineates tumor-T-cell dynamics in anti-PD-1-refractory melanoma treated with ipilimumab or ipilimumab plus nivolumab
Journal Articles

Abstract 674: CRISPR and drug screens identify ERK as the mediator of IFNg-induced melanoma growth inhibition

Ameya S. Champhekar, Rachel Heymans, Cynthia Gonzalez, Guillem Turon Font, Daniel Karin, June Lee, Robert Damoiseaux, Antoni Ribas
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 674.
https://doi.org/10.1158/1538-7445.AM2023-674
Published: 04 April 2023
View articletitled, Abstract 674: CRISPR and drug screens identify ERK as the mediator of IFNg-induced melanoma growth inhibition
Journal Articles

Abstract 914: Preinfusion polyfunctional profiles and cytokine secretion activity of transgenic TCR-T cells, and serum cytokine profiles, are associated with clinical outcomes in sarcoma and melanoma

Cole W. Peters, Crystal Quiros, Edward X. Han, Moe Kawakami, Conner Kidd, Alexandra Klomhaus, Antoni Ribas, Theodore S. Nowicki
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 914.
https://doi.org/10.1158/1538-7445.AM2023-914
Published: 04 April 2023
View articletitled, Abstract 914: Preinfusion polyfunctional profiles and cytokine secretion activity of transgenic TCR-T cells, and serum cytokine profiles, are associated with clinical outcomes in sarcoma and melanoma
Journal Articles

Abstract 2325: IRF1 displays opposing tumor cell-intrinsic and -extrinsic roles in anti-tumor immunity

Prabhat Kumar Purbey, Manash K. Paul, Keisuke S. Iwamoto, Allison Daly, Joowon Seo, Ameya S. Champhekar, Katie Campbell, Dorthe Schaue, William H. McBride, Steven M. Dubinett, Antoni Ribas, Stephen T. Smale, Philip O. Scumpia
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 2325.
https://doi.org/10.1158/1538-7445.AM2023-2325
Published: 04 April 2023
View articletitled, Abstract 2325: IRF1 displays opposing tumor cell-intrinsic and -extrinsic roles in anti-tumor immunity
Journal Articles

Abstract 3275: Combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607

Siwen Hu-Lieskovan, James Moon, John Hyngstrom, Katie M. Campbell, Gino K. In, Theodore F. Logan, Kari L. Kendra, Ding M. Wang, Douglas B. Johnson, Gary C. Doolittle, Alan Tan, Ann W. Silk, Kenneth F. Grossmann, Christopher W. Ryan, Sapna P. Patel, Shay Bellasea, Michael C. Wu, John M. Kirkwood, Helen X. Chen, Antoni Ribas
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3275.
https://doi.org/10.1158/1538-7445.AM2023-3275
Published: 04 April 2023
View articletitled, Abstract 3275: Combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607
Journal Articles

Abstract 109: Multi-modal single-cell analysis of immunotherapy-experienced cutaneous and mucosal melanoma

Jana Biermann, Yiping Wang, Linyue Fan, Patricia Ho, Amit D. Amin, Johannes C. Melms, Somnath Tagore, Kevin Hoffer-Hawlik, Parin Shah, Neha Shaikh, Priyanka Ramaradj, Mingxuan Zhang, Antoni Ribas, Caroline Robert, Elham Azizi, Benjamin Izar
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 109.
https://doi.org/10.1158/1538-7445.AM2023-109
Published: 04 April 2023
View articletitled, Abstract 109: Multi-modal single-cell analysis of immunotherapy-experienced cutaneous and mucosal melanoma
Journal Articles

Abstract 4527: CD8 T cell-melanoma cell interactions in response and resistance to ipilimumab plus nivolumab: Biopsy analysis of SWOG S1616

Katie M. Campbell, Lawrence Kuklinski, Zaid Bustami, Jessica Maxey, Egmidio Medina, Sandra Santulli-Marotto, Cynthia R. Gonzalez, Nataly Naser Aldeen, Kari Kendra, Sapna Patel, Siwen Hu-Lieskovan, James Moon, Shay Bellasea, Christine N. Spencer, Marshall A. Thompson, Michael Wu, Ari Vanderwalde, Philip O. Scumpia, Antoni Ribas
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4527.
https://doi.org/10.1158/1538-7445.AM2023-4527
Published: 04 April 2023
View articletitled, Abstract 4527: CD8 T cell-melanoma cell interactions in response and resistance to ipilimumab plus nivolumab: Biopsy analysis of SWOG S1616
Journal Articles

Abstract 3605: Human chimeric orthogonal IL9 receptor signaling promotes stemness and polyfunctionality for adoptive T cell therapy of cancer

Mito Tariveranmoshabad, Leon L. Su, Amy L. Sun, Lora K. Picton, Antoni Ribas, K. Christopher Garcia, Anusha Kalbasi
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3605.
https://doi.org/10.1158/1538-7445.AM2022-3605
Published: 15 June 2022
View articletitled, Abstract 3605: Human chimeric orthogonal IL9 receptor signaling promotes stemness and polyfunctionality for adoptive T cell therapy of cancer
Journal Articles

Abstract 3818: Infrequent chromosomal loss and recurrent gains lead to imbalanced expression of HLA genes in melanoma

Katie M. Campbell, Justin Saco, Egmidio Medina, Meelad Amouzgar, Shannon M. Pfeiffer, Cynthia R. Gonzalez, Gabriela Steiner, Ameya Champhekar, Cristina Puig Saus, Jesse Zaretsky, Gabriel Abril Rodriguez, Agustin Vega-Crespo, Ignacio Baselga Carretero, Mito Tariveranmoshabad, Anusha Kalbasi, Christine Spencer, Zachary L. Skidmore, Malachi Griffith, Obi L. Griffith, Daniel K. Wells, Antoni Ribas
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3818.
https://doi.org/10.1158/1538-7445.AM2022-3818
Published: 15 June 2022
View articletitled, Abstract 3818: Infrequent chromosomal loss and recurrent gains lead to imbalanced expression of HLA genes in melanoma
Journal Articles

Abstract 1215: pVACsplice: Predicting neoantigens from tumor-specific alternative splicing events derived from cis-acting regulatory mutations using whole exome and RNA sequencing data

Megan M. Richters, Kelsy C. Cotto, Susanna Kiwala, Huiming Xia, Beatriz M. Carreno, Gavin P. Dunn, Antoni Ribas, Obi L. Griffith, Malachi Griffith
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1215.
https://doi.org/10.1158/1538-7445.AM2022-1215
Published: 15 June 2022
View articletitled, Abstract 1215: pVACsplice: Predicting neoantigens from tumor-specific alternative splicing events derived from cis-acting regulatory mutations using whole exome and RNA sequencing data
Journal Articles

Abstract CT013: S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti-PD-1 therapy

Ari M. Vanderwalde, James Moon, Kari Kendra, Nikhil I. Khushalani, Frances Collichio, Jeffrey A. Sosman, Alexandra Ikeguchi, Adrienne I. Victor, Thach-Giao Truong, Bartosz Chmielowski, David C. Portnoy, Michael C. Wu, Kenneth F. Grossmann, Antoni Ribas
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT013.
https://doi.org/10.1158/1538-7445.AM2022-CT013
Published: 15 June 2022
View articletitled, Abstract CT013: S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti-PD-1 therapy
Journal Articles

Abstract 1388: Mutations in transcriptional activators of MHC I antigen presentation, NLRC5 and CIITA, are mutually exclusive and have different effects on melanoma gene transcripts

Mildred Galvez, Katie M. Campbell, Egmidio Medina, Antoni Ribas
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1388.
https://doi.org/10.1158/1538-7445.AM2022-1388
Published: 15 June 2022
View articletitled, Abstract 1388: Mutations in transcriptional activators of MHC I antigen presentation, NLRC5 and CIITA, are mutually exclusive and have different effects on melanoma gene transcripts
Journal Articles

Abstract 765: Hybridized-capture sequencing methods bias analysis of antigen presentation genes

Egmidio Medina, Katie Campbell, Antoni Ribas
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 765.
https://doi.org/10.1158/1538-7445.AM2022-765
Published: 15 June 2022
View articletitled, Abstract 765: Hybridized-capture sequencing methods bias analysis of antigen presentation genes